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Augmentation of tumour delivery of macromolecular drugs with reduced
bone marrow delivery by elevating blood pressure
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Summary Effects of angiotensin II (AT-II)-induced hypertension on the distribution of macromolecules to
Walker carcinoma and to bone marrow of SMANCS [poly(styrene-co-maleic-acid)-neocarzinostatin conjugate]
were investigated in rats. AT-II-induced hypertension from about 100 to 150 mmHg significantly increased the
accumulation of the macromolecular drug SMANCS and 5'Cr-labelled bovine serum albumin ([5'Cr]BSA),
representatives of macromolecular drugs, in tumour tissue. At I h after i.v. administration, intratumour
concentrations of [5'Cr]BSA and SMANCS were elevated by 1.2-1.8-fold. The higher drug accumulation in
the tumour that was produced by the artificial hypertension was retained even 6 h after administration. This
observation indicates an additive effect to that under normotensive conditions where intratumour macro-
molecular drug concentrations increase steadily during this period. Furthermore, distributions of these drugs in
the bone marrow and the small intestine decreased during artificial hypertension to 60-80% of those in the
normotensive state. Therefore, the drug concentration ratios of tumour/bone marrow and tumour/small
intestine were increased by 1.8-2.4-fold. A decreased distribution of SMANCS to normal tissues under
hypertensive conditions was also confirmed by the significant reduction of its toxicity e.g. leukopenia,
diarrhoea, and body weight loss, even at a lethal dose. On the contrary, [3H]methylglucose showed no
remarkable difference in tumour or bone marrow accumulation under this hypertensive condition. These
results show the advantages of macromolecules over small molecules for AT-II-induced hypertension
chemotherapy.
Selective drug targeting to a tumour is required for the
effective treatment of solid tumours. Ifthis objective could be
achieved, undesirable toxicities of a drug to normal tissues,
such as the bone marrow, will be reduced and therapeutic
efficacy will improve. We have developed an effective way of
achieving highly tumouritropic delivery of drugs by using
macromolecules and taking advantage of the unique charac-
teristics of the blood and lymphatic vasculatures of tumour
tissue (Maeda et al., 1979a,b; Takeshita et al., 1982; Maeda
et al., 1984; Matsumura & Maeda, 1986; Maeda & Mat-
sumura, 1989; Maeda, 1991; Maeda et al., 1992). Namely,
most solid tumours possess vasculature that is densely and
irregularly developed, and hyperpermeable to macromole-
cules; however, they usually lack functioning lymphatics,
which leads to selective deposition of macromolecules in
tumour tissues. We have adopted a term, enhanced perme-
ability and retention (EPR) effect, to describe this phen-
omenon (Maeda et al., 1984; Matsumura & Maeda, 1986;
Maeda & Matsumura, 1989; Maeda, 1991; Maeda et al.,
1992).
Antiontensin II (AT-II)-induced hypertension has been
proved to result in selective increase in the blood flow in
tumour tissue only and not in normal tissue (Suzuki et al.,
1981; Hori et al., 1991). Improved antitumour activity was
reported in the clinical setting by use of this AT-II method
(Wakui & Sato, 1984). The rationale behind this method is
based on a hypothesis that increased blood flow will cause a
parallel increase in the distribution of the drugs (Suzuki et
al., 1981; Wakui & Sato, 1984), because small molecular
drugs would diffuse freely in and out of the blood vessels.
Under these circumstances the AT-II method was explored
only for mostly conventional small molecular drugs (e.g.
doxorubicin, mitomycin C, etc.). However, it seems plausible
that their passive diffusion back into the blood circulation
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would clear these drugs from the tumour tissue rapidly when
plasma drug level drops.
The distribution of macromolecules, however, depends not
only on the blood flow but also on the enhanced permeability
of vasculature of the tumour tissues. Namely, vascular
permeability for macromolecules as well as lipid such as
Lipiodol is more enhanced in the tumour tissue, which
indicates more selective deposition of macromolecules and
lipids and more importantly little movement back into the
blood or into the lymphatic capillaries is taking place (Iwai et
al., 1984; Konno et al., 1984a; Maeda et al., 1984; Mat-
sumura & Maeda, 1986; Iwai et al., 1987; Maeda & Mat-
sumura, 1989; Maeda, 1991; Maeda et al., 1992). Thus, it
would be useful to study the influence of AT-IT-induced
hypertension on the distribution of macromolecules in
tumour and normal tissues.
For this study, we used [5'Cr]BSA and SMANCS as
representative macromolecules and [3H]methylglucose as a
model for small molecules with AT-II-induced hypertension
from about 100 to about 150mmHg. We also examined the
effect of the artificial hypertension on the various side effects
at or near lethal dose of SMANCS.
Materials and methods
Animals and tumour
We used female Wistar/Imamichi rats (200-250g), bearing
Walker 256 carcinoma. Walker 256 carcinoma cells were
maintained by serial i.p. passage. Cells (2 x 106) were injected
i.p. or s.c. into the rats, and 5 days later the drug treatments
were conducted. Usually, bloody ascites and a solid tumour
on the omentum weighing about 1 g had developed 5 days
later. This will therefore be a good model for peritoneal
dissemination of tumour.
Drugs and chemicals
AT-II (human) was purchased from Peptide Institute Inc.,
Osaka, Japan. 5"CrC13 and [3H]methylglucose were purchased
from ICN Biochemicals Inc., Costa Mesa, CA, USA.
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SMANCS, styrene-maleic acid copolymer-conjugated neocar-
zinostatin (Maeda et al., 1979a,b; Takeshita et al., 1982;
Maeda et al., 1984; Maeda et al., 1985) was a generous gift
from Kuraray Co., Ltd., Osaka, Japan. 5"Cr-labelled bovine
serum albumin ([51Cr]BSA) was prepared by modifying the
amino groups of bovine serum albumin (BSA) with anhyd-
ride of diethylenetriaminepentaacetic acid (DTPA) (protein/
DTPA molar ratio = 1/20) to form a DTPA-BSA conjugate.
DTPA was then chelated with 51Cr3+ as described previously
(Khaw et al., 1980; Hnatowich et al., 1982; Matsumura &
Maeda, 1986). Antibody to the neocarzinostatin portion of
SMANCS for quantification of SMANCS was kindly
donated by Pola Chemical Co. Ltd., Tokyo, Japan. All other
drugs and chemicals were from commercial sources.
Administration and quantification ofdrug
Anesthetised rats by s.c. administration of pentobarbital
sodium (30 mg kg-') were used as usual. [3H]Methyl-
glucose (2 x 106 d.p.m./rat), [51Cr]BSA (1 x 106 d.p.m./rat),
or SMANCS (10mgkg-') was injected i.v. via the tail vein
of rats under AT-IT-induced hypertensive conditions (140-
160 mmHg). The normotensive state (90-110 mmHg) was
altered by infusion of AT-II via the tail vein at a rate of
2.0-4.0 #tg kg-' min-', and the elevated blood pressure was
maintained for 15 min during injection of the drugs. The
blood pressure was monitored with an automatic tonometer
(PS-200, Riken Kaihatsu Co., Ltd., Tokyo, Japan). When the
infusion of AT-II stopped, the blood pressure returned to
normal values in 5-O min.
Rats were killed by i.v. administration of a lethal dose of
pentobarbital sodium (150 mg kg-') at 15, 20, 60, and
360min after drug administration to remove the tumour, the
bone marrow, the small intestine, and blood to determine the
drug concentration in these specimens. Concentrations of
[3H]methylglucose and [5'Cr]BSA were determined by coun-
ting the radioactivity as usual and that of SMANCS by
enzyme-linked immunosorbent assay (ELISA) using anti-
neocarzinostatin antibody and horseradish peroxidase-linked
anti-mouse immunoglobulin antibody.
Evaluation oftoxicities
SMANCS at a dose giving 50% lethality (LD50) (2 mgkg-')
was injected i.v. via the tail vein of normal rats without
tumour under hypertensive or normotensive conditions. The
AT-II infusion was continued for 15 min as described. After
24 h, body weight was measured and blood was collected for
determination of platelet and white blood cell (WBC) counts.
The frequency and severity of diarrhoea were also recorded.
Results
Distribution of[3H]methylglucose
Distribution of the radioactivity in the tumour and the bone
marrow was quantified at 15, 20, or 60 min after i.v. adminis-
tration of [3H]methylglucose under hypertensive or normo-
tensive conditions. As shown in Table I, the delivery of
[3H]methylglucose to tumour tissue at 15 min after admin-
istration was increased 20-25% by artificial hypertension. In
particular, the amount of radioactivity in subcutaneous
tumour was significantly increased by 1.26-fold, which was
observed only at 15 min after injection. However, no advan-
tage of artificial hypertension compared with normotensive
conditions was observed when the values were evaluated at
60 min after injection. The radioactivity of [3H]methylglucose
in tumour tissue decreased with time regardless of the blood
pressure at which the drug was administered.
AT-II-induced hypertension had little effect also on the
distribution of [3H]methylglucose in the bone marrow and
blood at 20 or 60min after injection.
Distribution of[5Cr]BSA and SMANCS
Results to reveal the effect of AT-II-induced hypertension on
the distribution of the macromolecule [5'Cr]BSA to tumour
and normal tissues are shown in Table II. The radioactivities
in the omentum tumour, the ascites, the bone marrow, and
of the blood at 1 and 6 h after i.v. administration of
[5'Cr]BSA under normotensive and induced hypertensive con-
ditions are given. Delivery of [5mCr]BSA to tumour tissue and
to the ascites increased by 1.8 and 1.3-fold, respectively,
under hypertensive compared with normotensive conditions
at 1 h. In contrast to the situation with [3H]methylglucose,
the amount of [5'Cr]BSA that was deposited in these tissues
increased with time, and the drug concentration in the
tumour increased significantly under hypertensive conditions
compared with that of the normotensive groups. The higher
values in the tumour tissue were retained even at 6 h after
administration.
It should be noted that AT-II-induced hypertension
resulted in less distrubtion of [5'Cr]BSA to the bone marrow
and the small intestine (64-74% of that under normotensive
conditions at 6 h). The values for the normal tissues showed
Table I Accumulation of [3H]methylglucose in tumour and bone marrow after i.v.
administration under AT-II-induced hypertensive conditions in rats
Ratio ofdistribution:
Specimen and % Ofinjected dose/g tissuea hypertension/normotension
time after injection Normotension Hypertension (fold increased)
Tumour, omentum
15 min 1.04 0.22 1.25 0.17 1.20
60 min 0.94 0.13 1.04 0.33 1.10
Tumour, s.c.
15 min 1.15 0.15 1.45 0.23b 1.26b
60min 0.85±0.19c 0.81 0.16c 0.96
Bone marrow
20 min 1.58 0.48 1.54 0.32 0.97
60min 1.45±0.51 1.70±0.17 1.11
Blood
20 min 1.08 ± 0.27 1.04 0.26 0.96
60min 1.09±0.37 1.12±0.24 1.03
aResults are expressed as mean values ± s.d. [3H]methylglucose (2 x 106 d.p.m.) was
injected i.v. during normotensive (90-110 mmHg) or AT-II induced hypertensive
(140-160 mmHg)conditions. InfusionofAT-I1wasmaintained tokeepthehypertensive
state for 15 min after injection of [3H]methylglucose. Rats were killed at the indicated
time after injection. Tumour, s.c. indicates tumour cells injected subcutaneously. Four
animals were used for each group and each animal was inoculated with two s.c. and one
omentum tumour. 6Significantly different from the value obtained under normotensive
conditions (P<0.01, Student's t-test). cSignificantly lower than the value obtained at
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Table II Accumulation of [51Cr]BSA in tumour and other tissues after i.v.
administration under AT-II-induced hypertensive conditions in rats
Ratio ofdistribution:
Specimen and % Ofinjected dose/g tissue' hypertension/normotension
time after injection Normotension Hypertension (fold increased)
Tumour, omentum
I h 0.26 0.05 0.46± 0.1lb 1.77b
6h 0.58±0.09c 0.70±0.10c 1.21
Ascites
I h 0.48 0.13 0.64 0.04b 1.33b
6 h 1.70 0.44c 2.07 0.22c 1.22
Bone marrow
1 h 0.23 + 0.02 0.19 0.02b 0.83b
6 h 0.09 ± 0.02c 0.06 0.01b,c 0.74b
Small intestine
I h 0.25 ± 0.01 0.23 ± 0.00 0.92
6 h 0.31 ±0.10 0.20 0.06 0.64
Blood
1 h 4.64 0.20 4.40 0.43 0.95
6 h 2.26 ± 0.53c 2.05 ± 0.29c 0.91
'Results are expressed as mean values ± s.d. [51Cr]BSA (1 x 106 d.p.m.) was injected
i.v. during normotensive (90-110 mmHg) or AT-II-induced hypertensive (140-
160 mmHg) conditions. Infusion of AT-II continued for 15 min after injection of
[5ICr]BSA. Rats were killed at 1 and 6 h after injection. Three or four rats were used for
each group with tumour in the omentum. bSignificantly higher or lower than the value
undernormotensiveconditions (P<0.05, Student's t-test). cSignificantly higherorlower
than the value obtained at 1 h (P<0.05, Student's t-test).
no increase in the amount of the drug with time. Similar
results were obtained when we examined the distribution of
Evans blue, which binds to and behaves like albumin (Maeda
et al.,1992): i.e. there was less accumulation in the bone
marrow after i.v. injection under the same conditions des-
cribed above by the EPR effect (data not shown).
We also tested the effect of AT-II-induced hypertension on
the distribution of the macromolecular anticancer agents,
SMANCS (16,000Da) (Maeda et al., 1979a; Maeda et al.,
1985), which is known to bind to albumin in the blood
stream and hence behaves similar to albumin (Kobayashi et
al., 1988). Table III shows the concentration of SMANCS in
the tumour, the bone marrow, and the small intestine at 1
and 6 h after injection, as determined by ELISA. The dis-
tribution of SMANCS to tumour was augmented signifi-
cantly over time even under normotensive conditions, but it
was enhanced even further under AT-II-induced hyperten-
sion. In contrast, distribution to bone marrow or small intes-
tine tended to be reduced at 1 h after injection. Furthermore,
enhanced intratumour concentration of the drug by using
artificial hypertension was retained for 6 h, which is consis-
tent with the results for [5'Cr]BSA. However, EPR effect
alone facilitated much more (about 7-fold) accumulation of
these macromolecules in tumour tissue over the bone mar-
row, or tumour over the intestine about 2-fold, where
induced hypertension augmented EPR effect only about 2-
fold.
The distribution ratios (tumour vs the normal tissues) of
these macromolecules were calculated: namely, their concen-
tration in tumour was divided by that in the bone marrow or
the small intestine for each animal. As shown in Figure 1,
selective accumulation of [51Cr]BSA in the tumour was
improved about 1.5-2-fold under AT-II-induced hyperten-
sion at both 1 and 6 h. Tumour-specific accumulation of
SMANCS was also augmented by about 30-160% under
artificial hypertension (Figure 2).
Table III Enhanced accumulation of SMANCS in tumour and reduction in normal
tissues after i.v. administration under AT-lI-induced hypertensive conditions in rats
Ratio ofdistribution:
Specimen and % Ofinjected dose/g tissue' hypertension/normotension
time after injection Normotension Hypertension (fold increased)
Tumour, s.c.
I h 0.29 ± 0.09 0.44 0.17b 1.63b
6 h 0.77 0.51 0.95 0.48c 1.23
Tumour, omentum
1 h 0.26 ± 0.20 0.33 ± 0.28 1.27
6 h 0.48 ± 0.28 0.88 0.28b,c 1.80b
Bone marrow
I h 0.24±0.07 0.17±0.10 0.71
6 h 0.13 0.06 0.14 0.06 1.12
Small intestine
1 h 0.11 ± 0.05 0.07 0.03 0.64
6 h 0.05 ± 0.02 0.05± 0.01 0.98
Blood
1 h 3.03 ± 0.68 3.06 ± 0.73 1.01
6h 1.15+ 1.05c 1.27±0.74c 1.10
'Results are expressed as mean values ± s.d. SMANCS (10 mgkg-') was injected i.v.
duringnormotensive (90-110 mmHg) orAT-II-induced hypertensive(140-160 mmHg)
conditions. InfusionofAT-II continued for 15 minafterinjectionofSMANCS. Fiverats
were used for each group and each rat had two s.c. and one omentum tumour.
bSignificantly different from the value under normotensive conditions (P<0.05,
Student's t-test). cSignificantly higher or lower than the value obtained at 1 h (P<0.05,
Student's t-test).978 C.J. LI et al.
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Figure 1 Tumour-specific increase in accumulation of [5"Cr]BSA
after i.v. administration under AT-1I-induced hypertensive condi-
tions in rats. The concentration of [5'Cr]BSA in omentum tumour
(Tu,om.) was divided by that in the bone marrow (B.marrow) or
the small intestine (Sm.int.) for each animal to obtain the dis-
tribution ratio of [51Cr]BSA; ["'Cr]BSA was administered under
normotensive (0) or hypertensive (U) conditions. Each column
shows the distribution ratio at 1 or 6 h after administration. Bars
indicate s.d. Every value obtained at 6 h was significantly higher
than that at I h in each condition (P<0.05, Student's t-test). #
indicates that the value under hypertensive condition is
significantly higher than that for the normotensive control
(P<0.05, Student's t-test).
Toxic effects ofa lethal dose ofSMANCS under
AT-II-induced hypertension
We examined the effect of induced hypertension on the side
effects of SMANCS at a lethal dose. As shown in Table IV,
side effects such as leukopenia, diarrhoea, and body weight
loss induced by high dose of SMANCS were significantly
reduced under AT-Il-induced hypertension. Thrombocyto-
penia was also reduced by this method, although the
difference was statistically insignificant.
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Discussion
As reported by Suzuki et al. (1981) and Hori et al. (1991),
AT-II-induced hypertension produces a selective increase in
blood flow volume in tumour tissue because of the absence of
autoregulation of tumour blood flow. In great contrast, nor-
mal tissue has an autoregulatory flow volume regardless of
the blood pressure applied. An increase in blood flow is
expected to result in increased drug delivery to tumour. On
the basis of this principle, AT-IL-induced hypertensive
chemotherapy has been initiated in Japan (Sato et al., 1981).
It is anticipated, however, that low-molecular-weight
anticancer agents would traverse so freely out of the inter-
stitial space back into the blood stream because of the con-
centration gradient that it may be difficult to retain higher
drug concentrations in the tumour for an appreciable period
after termination of AT-II infusion. By using high-molecular-
weight drugs, we anticipated to circumvent this drawback
knowing the EPR effect would take place for mac-
romolecules. The results showed that artificial hypertension
indeed induced the enhanced accumulation of [3H]methyl-
glucose in tumour tissue only at the early time point
(15 min), however, this gain disappeared in 1 h, as shown in
Table I. [3H]Methylglucose may have been drained out of
tumour tissue perhaps through both blood and lymphatic
capillaries into the blood stream.
In contrast to these results with [3H]methylglucose, a clear
difference and advantage was obtained by the use of artificial
hypertension in the intratumour concentrations of both
macromolecules at 1 h, and which was well maintained even
at 6 h after injection (Tables II and III). In general, macro-
molecules and lipids in the interstitial space are known to be
recovered mainly by the lymphatics in normal tissues (Cour-
tice, 1963), but they seemed unlikely to be cleared from
tumour tissue effectively (Iwai et al., 1984; Iwai et al., 1987;
Maeda et al., 1984; Matsumura & Maeda, 1986). If the
accumulated macromolecules in tumour could be drained by
the operating lymphatics there would be no accumulation of
the macromolecular drugs as in normal tissue. The results
showed, however, that this appears to be unlikely because of
the high accumulation in tumour (Tables II and III, Figures
1 and 2). This result suggests that little lymphatic drainage is
taking place from tumour tissue. Furthermore, in contrast to
1 h 6h 1 h 6h 1 h 6h 1 h 6h
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Figure 2 Tumour-specific increase in accumulation of SMANCS after i.v. administration under AT-TI-induced hypertensive
conditions in rats. The concentration of SMANCS in subcutaneious tumour (Tu,s.c.) or omentum tumour (Tu,om.) was divided by
that in the bone marrow (B.marrow) or the small intestine (Sm.int.) for each animal to obtain the distribution ratio of SMANCS.
SMANCS was administered i.v. under normotensive (0) or hypertensive (-) conditions. Each column shows the distribution ratio
at 1 or 6 h after administration. Bars indicate s.d. Every value obtained at 6 h was significantly higher than that at 1 h in each
condition (P<0.05, Student's t-test). # indicates that the values under hypertensive conditions are significantly higher than those
for the normotensive control (P<0.05, Student's t-test).TUMOUR TARGETING BY INDUCED HYPERTENSION 979
Table IV Reduced toxicity of SMANCS with AT-II-induced hypertension in healthy rats
Treatment Increase in body wt (g) Platelet ( x 10J1 l) WBC (mM3) Diarrhoea (%)
Control, 1.5 0.7 1 98.9 23.8 10733 902 1 _ 0 -1 normotensive a b b c
SMANCS, -7.4 4.3 53.9 8.8 3133 306 J - 80 1
normotensive a b c
SMANCS + AT-II, 0.6 ± 0.9 -J 73.8 ± 26.3 4267 ± 231 J 0
hypertensive
SMANCS (2mgkg-') was injected i.v. under AT-Il-induced hypertensive (140-160mmHg) or normotensive
(90-110 mmHg) conditions asdescribed in Tables I-IL. Values aremeans ± s.d. at 24 h after treatment. Five rats for
each group.
a, b, and c Significantly different between the values indicated. ap<0.02; bp<0.001; Cp<0.01.
the intratumour concentration of [3H]methylglucose, which
decreased more rapidly with time (Table I), in intratumour
concentration of [51Cr]BSA and SMANCS, compared with
that in normal tissue, increased with time (Figures 1 and 2)
as previously observed (Maeda et al., 1984; Matsumura &
Maeda, 1986) and attributed to the EPR effect.
The results became more pronounced when the blood pres-
sure was increased while drugs were administered (Tables II
and III). Unlike small molecules, macromolecules and lipids
themselves are tumouritropic because of the EPR effect, as
reported previously (Maeda et al., 1984; Matsumura &
Maeda, 1986; Maeda & Matsumura, 1989; Maeda, 1991;
Maeda et al., 1992). Using another macromolecule (hydroxy-
propylmethacrylamide copolymer) developed by a joint effort
of groups in the UK and Czechoslovakia, we also observed a
time-dependent increase in intratumour concentration (EPR
effect) (Seymour, L., Miyamoto, Y., et al., unpublished).
We have also found another phenomenon that little lym-
phatic clearance of lipids (Konno et al., 1984a,b; Iwai et al.,
1984; Maeda et al., 1984; Iwai et al., 1987) and mac-
romolecules (Maeda et al., 1984; Matsumura & Maeda, 1986;
Maeda & Matsumura, 1989; Maeda, 1991) from solid
tumours takes place.
The EPR effect can be attributed to a hypervascularised
state resulting from tumour angiogenesis (Folkman & Klag-
sbrun, 1987), and incomplete vascular architecture and
leakiness (Suzuki et al., 1987; Skinner et al., 1990). Further-
more, we found a mechanism that allows a high local
concentration of bradykinin which enhances vascular perme-
ability; in which tumour cells activate the Hageman factor/
kallikrein/kinin cascade (Maeda et al., 1988; Matsumura et
al., 1988; Matsumura et al., 1990; Matsumura et al., 1991).
As a consequence, vascular permeability will be elevated.
Another permeability-enhancing factor that would function
in an additive manner to the kinin system is also known
(Senger et al., 1983; Dvorak et al., 1985).
It is suggested that the major obstacle to the delivery of
macromolecules to solid tumours is the elevated interstitial
fluid pressure in tumour tissues (Jain, 1990). Our work des-
cribed here indicates that AT-II-induced hypertension is an
effective way for overcoming such an obstacle of intra-
tumoural fluid pressure by increasing blood pressure/flow/
vascular surface area in tumour tissue (Suzuki et al., 1981;
Hori et al., 1983; Hori et al., 1984), which may all enhance
the convective influx of macromolecules into the tumour
compartment out of the blood capillary. Present and
previous observations of EPR effect or higher retention in
tumour indicate reverse transfer of macromolecules and
lipids does not seem to occur as a vascular barrier or charac-
teristics.
The results described here also imply that this method may
improve the delivery of monoclonal antibodies to tumour
tissue. Several approaches have been examined to increase
the tumour uptake of monoclonal antibodies so far (e.g.
Smyth et al., 1987; Kalofonos et al., 1990; Cope et al., 1990;
Russel et al., 1990). Recently we reported that ATI-IT-
induced hypertension combined with the use of kininase
inhibitor enhanced the tumour localisation of a monoclonal
antibody up to 200% of control (Noguchi et al., 1992).
Kininase inhibitor might enhance the vascular permeability
by prolonging the action of kinin (Maeda et al., 1988; Mat-
sumura et al., 1988; Matsumura et al., 1990; Matsumura et
al., 1991).
The second advantage clarified in this study was the reduc-
tion in accumulation of the drug by normal tissues, such as
the bone marrow and the small intestine, by using macro-
molecular drugs rather than small molecules in induced
hypertension chemotherapy. AT-II-induced hypertension de-
creased the blood flow volume in the kidneys because of
vascular constriction, resulting in reduced renal toxicity of
cisplatin (Kuroiwa et al., 1987). In general, however, arterial
blood flow remains constant in normal tissues, in the range
between 50 and 150 mmHg, by autoregulatory contraction of
arterioles as described above (Suzuki et al., 1981), with some
exceptions such as the kidney (Kuroiwa et al., 1987). It is
consistent then that accumulation of [3H]methylglucose in
bone marrow was little affected by manipulating blood pres-
sure, as shown in Table I. In contrast to the accumulation of
[3H]methylglucose, the accumulation of macromolecules
represented by [5'Cr]BSA and SMANCS in the bone marrow
was reduced under hypertensive conditions as shown in
Tables II and III. A decrease in the distribution of macro-
molecules to normal tissues under AT-TI-induced hyperten-
sion was confirmed by the reduction of the toxicity of
SMANCS administered at a lethal dose (Table IV).
Significant protection against leukopenia, diarrhoea, and loss
of body weight was noted, reflecting the reduced delivery of
SMANCS to these organs (Table III). Accordingly, AT-TI-
induced hypertension can improve the therapeutic index of
macromolecular anticancer agents.
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